Clinical trial results showed that AstraZeneca’s Farxiga treatment against Type II diabetes significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction.
HFpeF is a condition in which the left ventricle of the heart hardens, becoming less able to relax, which in turn provokes higher blood pressure.
The results of the third phase clinical trial were presented at the European Society of Cardiology Congress 2022 on Tuesday, in Barcelona, Spain, simultaneous to their publication in the New England Journal of Medicine.
— More to follow —
